Ashkon Software



EBIO - Eleven Biotherapeutics, Inc.

EBIO Stock Chart

EBIO Profile

Eleven Biotherapeutics, Inc. logo

Eleven Biotherapeutics, Inc. (EBIO) is a clinical-stage biopharmaceutical company that is focused on developing innovative protein-based therapies for the treatment of cancer and other diseases. The company's product candidates are designed to target specific proteins that are involved in the progression of certain diseases.

Eleven Biotherapeutics' lead product candidate is Vicinium, a protein-based therapy designed to target and kill cancer cells in patients with non-muscle invasive bladder cancer. The company is also developing other product candidates, including a treatment for wet age-related macular degeneration.

Eleven Biotherapeutics was founded in 2010 and is headquartered in Cambridge, Massachusetts. As of September 2021, the company was conducting clinical trials for its product candidates and had not yet generated significant revenue. The company's revenue for the fiscal year 2020 was $1.4 million, representing a decline from $4.4 million in the previous year. Net loss for the same period was $24.3 million, a decline from a net loss of $34.9 million in the previous year.

Eleven Biotherapeutics has a market capitalization of approximately $15 million as of my knowledge cutoff of September 2021, and its stock is listed on the NASDAQ stock exchange under the ticker symbol EBIO.

The biopharmaceutical industry is subject to various risks, including regulatory risks, competitive risks, and clinical trial risks. However, Eleven Biotherapeutics' focus on developing innovative protein-based therapies and its efforts to advance its product candidates through clinical trials should position it for improved performance in


Copyright © 2000-2024, Ashkon Software LLC
Privacy Policy | Refund Policy | Disclaimer